Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Campath enters phase I/II trial in NHL

Jan. 3, 2003

NeoPharm seeks FDA guidance on IL-13-PE38 trial design and registration plan

Dec. 30, 2002

Siplizumab combined with stem cell transplantation in refractory NHL

Dec. 23, 2002

New data on the combination of unlabeled and I131-labeled tositumomab in NHL

Dec. 23, 2002

Positive interim results for AG-858/Gleevec combination therapy in CML

Dec. 20, 2002

Epratuzumab safe and effective in non-Hodgkin's lymphoma

Dec. 20, 2002

Phase I clinical testing commences for two Igeneon cancer products

Dec. 20, 2002

HER-2 DNA AutoVac therapeutic vaccine safe and immunogenic in breast cancer patients

Dec. 19, 2002

Modified dosing schedule of apolizumab allows higher doses in CLL and ALL

Dec. 19, 2002

Trifunctional bispecific antibody shows potential for B-cell lymphoma

Dec. 18, 2002

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...